Home › Diffuse Large B-Cell Lymphoma › Illinois › Chicago
Diffuse Large B-Cell Lymphoma clinical trials in Chicago, IL
18 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
RecruitingPhase 2
- Northwestern University, Chicago
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
RecruitingPhase 2
- University of Chicago Medical Center ( Site 0126), Chicago
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecruitingPhase 1
- The University of Chicago Medical Center (UCMC), Chicago
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
RecruitingPhase 1
- University of Chicago Comprehensive Cancer Center, Chicago
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RecruitingPhase 2
- Northwestern University - Feinberg School of Medicine, Chicago
- Rush University Medical Center, Chicago
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
RecruitingPhase 1/2
- University of Chicago, Chicago
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RecruitingPhase 1/2
- University of Chicago Medical Center, Chicago
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
RecruitingObservational study
- Robert H Lurie Cancer Center, Chicago
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RecruitingPhase 3
- Northwestern, Chicago
- University of Chicago, Chicago
DALY II USA/ MB-CART2019.1 for DLBCL
RecruitingPhase 2
- Robert H Lurie Cancer Center, Chicago
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
RecruitingPhase 1
- University of Illinois at Chicago, Chicago
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
RecruitingPhase 1
- Northwestern University, Chicago
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RecruitingPhase 1
- Northwestern University, Chicago
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
RecruitingPhase 1/2
- University of Illinois at Chicago Cancer Center, Chicago
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RecruitingPhase 1
- The University of Chicago Medical Center, Chicago
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
RecruitingPhase 2
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
RecruitingPhase 2
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
RecruitingPhase 1
- University of Chicago, Chicago
Diffuse Large B-Cell Lymphoma trials in other cities
- New York City, NY21 studies
- Baldwin Park, CA19 studies
- Houston, TX17 studies
- Los Angeles, CA17 studies
- Milwaukee, WI16 studies
- Boston, MA16 studies
- Philadelphia, PA15 studies
- Portland, OR15 studies
- Durham, NC14 studies
- Nashville, TN14 studies
- Dallas, TX13 studies
- Seattle, WA12 studies
Other studies in Chicago
- Non-Small Cell Lung Cancer62 studies
- Breast Cancer58 studies
- Cancer (all types)53 studies
- Metastatic Cancer45 studies
- Prostate Cancer45 studies
- Obesity42 studies
- Lung Cancer41 studies
- Ovarian Cancer36 studies
- Stroke35 studies
- Heart Failure32 studies
- Colorectal Cancer32 studies
- Overweight28 studies
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.